Feasibility of Therapy With Hypomethylating Agents in Patients With Renal Insufficiency
Authors:
- Hagop KantarjianHKHagop Kantarjian
- Jean-Pierre IssaJIJean-Pierre Issa
- Elias JabbourEJElias Jabbour
- Fabio P.S. SantosFSFabio P.S. Santos
- Deborah McCueDMDeborah McCue
- Guillermo Garcia-ManeroGGGuillermo Garcia-Manero
- Sherry PierceSPSherry Pierce
- Susan O'BRienSOSusan O'BRien
- Jorge E. CortésJCJorge E. Cortés
- Farhad RavandiFarhad Ravandi
- 1 June 2010
- journal article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 10 (3) , 205-210
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Estimation of creatinine clearance in morbidly obese patientsAmerican Journal of Health-System Pharmacy, 2009
- Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndromeCancer, 2007
- Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood, 2006
- Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaBlood, 2006
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006
- Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic SyndromesThe Journal of Clinical Pharmacology, 2005
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002
- DNMT1 and DNMT3b cooperate to silence genes in human cancer cellsNature, 2002
- Kinetics of phosphorylation of 5-aza-2′-deoxycytidine by deoxycytidine kinaseBiochemical Pharmacology, 1979